King Chulalongkorn Memorial Hospital is a public general and tertiary referral hospital in Bangkok, Thailand. It is operated by the Thai Red Cross Society, and serves as the teaching hospital for the Faculty of Medicine, Chulalongkorn University and Srisavarindhira Thai Red Cross Institute of Nursing.

There are 1,435 beds in King Chulalongkorn Memorial Hospital.

During the past decade, King Chulalongkorn Memorial Hospital conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 3 clinical trials were completed. i.e. 60% of trials that started reached the finish line.

Out of the total clinical trials conducted in "King Chulalongkorn Memorial Hospital" #1 sponsor was "Chulalongkorn University" with 6 trials, followed by "King Chulalongkorn Memorial Hospital" with 3 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 2 trials sponsored, "F2G Biotech GmbH" with 2 trials sponsored and "Arena Pharmaceuticals" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "King Chulalongkorn Memorial Hospital" #1 collaborator was "Iqvia Pty Ltd" with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Thammasat University" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "King Chulalongkorn Memorial Hospital" are "Ulcerative Colitis" (2 trials), "Adult-Onset Immunodeficiency With Acquired Anti-Interferon-Gamma Autoantibodies" (1 trials), "Adverse Effect of Diagnostic Agents, Subsequent Encounter" (1 trials), "Atrial Fibrillation" (1 trials) and "Biliary Stones" (1 trials). Many other conditions were trialed in "King Chulalongkorn Memorial Hospital" in a lesser frequency.

Most popular intervention types in "King Chulalongkorn Memorial Hospital" are "Drug" (9 trials), "Procedure" (2 trials), "Behavioral" (1 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Avelumab" (2 trials), "Etrasimod" (2 trials), "Placebo" (2 trials), "5-Fluorouracil" (1 trials) and "AmBisome®" (1 trials). Other intervention names were less common.

The vast majority of trials in "King Chulalongkorn Memorial Hospital" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "King Chulalongkorn Memorial Hospital". undefined are not yet recruiting, 4 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 9 completed trials in King Chulalongkorn Memorial Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in King Chulalongkorn Memorial Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".